Latar belakang: Infeksi TB (TB) dan Human Immunodeficiency Virus (HIV) masih menjadi masalah penyakit menular terbanyak di negara berkembang termasuk Indonesia. Insidens nasional koinfeksi TB-HIV sebanyak 36% dan angka kematian koinfeksi TB-HIV 9,3%. Insidens nasional TB resistan obat yang masih menjadi ancaman saat ini sebesar 23% dan semakin mempersulit keadaan tersebut. Keberhasilan pengobatan koinfeksi TB resistan obat-HIV di Indonesia sejauh ini masih belum diketahui.Tujuan: Penelitian ini bertujuan untuk memprediksi keberhasilan pengobatan pasien koinfeksi TB resistan obat HIV serta faktor yang mempengaruhi.Metode: Penelitian ini adalah penelitian retrospektif potong lintang menggunakan data rekam medis, eTB manager dan data penunjang pasien koinfeksi TB resistan obat-HIV yang berobat di Rumah Sakit Pusat Rujukan Respirasi Nasional Persahabatan Jakarta, Indonesia sejak tahun 2013-2019 untuk evaluasi keberhasilan pengobatan dan faktor yang mempengaruhi.Hasil: Pada penelitian ini didapatkan 63 pasien koinfeksi TB resistan obat HIV. Paisen terbanyak laki-laki (77,8%) dengan median usia 32 tahun. Pada akhir pengobatan didapatkan sebanyak 16 pasien (25,4%) berhasil menyelesaikan pengobatan. Faktor yang berkaitan terhadap keberhasilan pengobatan adalah status pekerjaan (p=0,000), status pernikahan (p=0,035), gejala akhir pengobatan (p=0,000), waktu konversi dan total lama pengobatan (p=0,013).Kesimpulan: Pada penelitian ini didapatkan bahwa keberhasilan pengobatan pasien koinfeksi TB resistan obat HIV masih rendah (25,4%) yang dipengaruhi oleh faktor status pekerjaan, status pernikahan, gejala akhir pengobatan, waktu konversi dan total lama pengobatan......Background: Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) infections remain the largest communicable disease problem in developing countries, including Indonesia. The national incidence of TB-HIV co-infection is 36% and the mortality rate of TB-HIV coinfections is 9,3%. The threat of drug resistance TB which it national incidence is 23%, further complicate this situation. The success rate of drug resistant TB-HIV coinfection treatment in Indonesia, to our extent, is yet to be known.Aim: This study aims to estimate the treatment success rate of drug resistance TB- HIV coinfection and realted factors influencing its outcomes.Method: This retrospective cross sectional study used hospital medical records, eTB manager and additional data of TB-HIV coinfected patients treated at Persahabatan Hospital Jakarta, Indonesia, between 2013 and 2019, to observe the treatment success and its related factors.Result: Sixty-three patients were drug resistance TB-HIV coinfected. Patients mostly men (77,8%) and were of median age of 32 years old. By the end of their treatments. 16 patients (25,4%) were completing their treatment. Factor correlated to the treatment success were employement status (p=0,046), marital status (p=0,035), final symptoms by the end of their treatment (p=0.000), convertion time and treatment total duration (p=0,013).Conclusion: This study found that the treatment success rate of drug resistance TB-HIV coinfection was 25,4%. Its contributing factors included employment status, marital status, final symptoms by the end of their treatment, convertion time and treatment total duration.